Zacks Small Cap Research – NWTG: Newton Golf’s Strong Revenue Growth Supports Price Target of $12.00 – Go Health Pro

Zacks Small Cap Research – NWTG: Newton Golf’s Strong Revenue Growth Supports Price Target of .00 – Go Health Pro

By Thomas Kerr, CFA NASDAQ:NWTG READ THE FULL NWTG RESEARCH REPORT 4th Quarter 2024 Financial Results On March 31, 2025, Newton Golf Company (NASDAQ:NWTG) reported 4th quarter and full year 2024 financial results which show strong revenue growth and a substantial increase in gross margins. Revenues in the 4th quarter increased to $1.07 million, an … Read more

Zacks Small Cap Research – LGMK: Potential Revenue Catalysts: GSA Approval, Medicaid Waivers, Device Upgrades – Go Health Pro

Zacks Small Cap Research – LGMK: Potential Revenue Catalysts: GSA Approval, Medicaid Waivers, Device Upgrades – Go Health Pro

By M. Marin NASDAQ:LGMK READ THE FULL LGMK RESEARCH REPORT Recent introduction of next-gen Guardian Alert 911 Plus in 1Q25… LogicMark, Inc. (NASDAQ:LGMK) launched the next generation of the Guardian Alert 911 Plus in February 2025. The next-generation Guardian Alert 911 Plus expands the company’s product suite and offers an upgrade from the earlier version … Read more

Zacks Small Cap Research – CTSO: CytoSorbents Reports 4th quarter and 2024 Financial Results Which Showed Impressive Product Revenue Growth That Exceeded Our Expectations. – Go Health Pro

By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT Update on the DrugSorb-ATR Regulatory Process Management reiterated that their De Novo DrugSorb-ATR submission continued to be in interactive review with FDA, that their Medical Device License application to Health Canada was in advanced review, and that they continue to expect regulatory decisions in … Read more

Zacks Small Cap Research – TSEM: Tower Expects Increasing Revenue in 2025 as Capacity Kicks In – Go Health Pro

By Lisa Thompson NASDAQ:TSEM READ THE FULL TSEM RESEARCH REPORT Tower (NASDAQ:TSEM) continued year-over-year revenue growth in Q4 2024 and expects that to continue sequentially and year-over-year throughout 2025. The growth will be back-half weighted as capacity comes online in Italy, Texas, and Japan. For the 2024 year, revenues and earnings were basically flat with … Read more

Zacks Small Cap Research – CTSO: CytoSorbents Reports Preliminary 4th Quarter and 2024 Financial Results Which Showed Impressive Product Revenue Growth That Exceeded Our Expectations. – Go Health Pro

By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT On January 3, 2025, CytoSorbents (NASDAQ:CTSO) reported strong preliminary 4th quarter and full year 2024 financial results which exceeded our expectations. 4th quarter product revenue (excluding grant income) is estimated to be in the range of $9.0-$9.2 million, which is approximately 22% to 25% … Read more